API maker Hovione moves into particle design

Portuguese API maker Hovione has invested in crystal design and particle size reduction to the nanoscale size and amorphose solid dispersion so it can offer those capabilities for the lab or commercial scale-up. The company tells in-PharmaTechnologist that it was hearing from customers that they needed the capability to handle "highly potent compounds." The publication points out that Hovione has been putting attention on solubility solutions. Last year, it struck a deal with Particle Sciences ($PSI) that allowed it to offer scale-up manufacturing services for solubilization processes developed by PSI. Story | More

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.